OGT inhibitors improve killing of cancer cells by PI3K inhibitors, suggesting OGT mediates resistance to PI3K inhibitors and possibly identifying a strategy to improve outcomes with kinase inhibitors in CLL patients (211, 212). This evidence concerns the gene OGT and B-cell chronic lymphocytic leukemia.